YU23499A - Inhibitorski amidi apo-b-sekrecije/mtp-a - Google Patents

Inhibitorski amidi apo-b-sekrecije/mtp-a

Info

Publication number
YU23499A
YU23499A YU23499A YU23499A YU23499A YU 23499 A YU23499 A YU 23499A YU 23499 A YU23499 A YU 23499A YU 23499 A YU23499 A YU 23499A YU 23499 A YU23499 A YU 23499A
Authority
YU
Yugoslavia
Prior art keywords
inhibitors
compounds
hmg
useful
apo
Prior art date
Application number
YU23499A
Other languages
English (en)
Inventor
George Chang
George Joseph Quallich
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of YU23499A publication Critical patent/YU23499A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Ovaj pronalazak se odnosi na jedinjenja formule (I) ili njegove stereoizomere, farmaceutski prihvatljive soli ili hidrate. Jedinjenja su Apo B/MTP inhibitori i korisna su u lecenju razlicitih poremecaja i stanja kao sto su ateroskleroza, pankreatitis, gojaznost, hiperholesteremija, hipertrigliceridemija, hiperlipi-demija i diabetes. Jedinjenja ovog pronalaska su takodje korisna u kombinaciji sa drugim farmaceutskim agensima koji ukljucuju biosintezu inhibitora holesterola i inhibitore absorpcije holesterola, narocito inhibitore HMG-CoA reduktaze i inhibitore HMG-CoA sintaze; inhibitora HMG-CoA reduktaze ekspresije gena; CETP inhibitore; pasivatore zucne kiseline; fibrate; inhibitore absorpcije holesterola; ACAT inhibitore, inhibitore sintetaze skvalena, recine razmene jona, anti oksidante i niacin. Ovaj pronalazak je takodje usmeren na intermedijare i postupke korisne za dobijanje jedinjenja formule (I).
YU23499A 1996-11-27 1997-11-03 Inhibitorski amidi apo-b-sekrecije/mtp-a YU23499A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3230796P 1996-11-27 1996-11-27

Publications (1)

Publication Number Publication Date
YU23499A true YU23499A (sh) 2001-07-10

Family

ID=21864233

Family Applications (1)

Application Number Title Priority Date Filing Date
YU23499A YU23499A (sh) 1996-11-27 1997-11-03 Inhibitorski amidi apo-b-sekrecije/mtp-a

Country Status (34)

Country Link
US (1) US6121283A (sh)
EP (1) EP0944602A1 (sh)
JP (1) JP3270764B2 (sh)
KR (1) KR100334567B1 (sh)
CN (2) CN1238764A (sh)
AP (1) AP804A (sh)
AR (1) AR010309A1 (sh)
AU (1) AU716151B2 (sh)
BG (2) BG108830A (sh)
BR (1) BR9714364A (sh)
CA (1) CA2272719C (sh)
CZ (1) CZ292160B6 (sh)
DZ (1) DZ2358A1 (sh)
EA (1) EA001539B1 (sh)
GT (1) GT199700122A (sh)
HN (1) HN1997000144A (sh)
HR (1) HRP970642A2 (sh)
ID (1) ID18995A (sh)
IL (1) IL129744A0 (sh)
IS (1) IS5040A (sh)
MA (1) MA26451A1 (sh)
NO (1) NO312760B1 (sh)
NZ (1) NZ335162A (sh)
OA (1) OA11050A (sh)
PA (1) PA8441601A1 (sh)
PE (1) PE17199A1 (sh)
SK (1) SK65499A3 (sh)
TN (1) TNSN97193A1 (sh)
TR (1) TR199901180T2 (sh)
TW (1) TW502023B (sh)
UY (1) UY24789A1 (sh)
WO (1) WO1998023593A1 (sh)
YU (1) YU23499A (sh)
ZA (1) ZA9710641B (sh)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262277B1 (en) 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
ATE233734T1 (de) * 1995-06-07 2003-03-15 Pfizer Biphenyl-2-carbonsäure-tetrahydro-isochinolin-6 yl amid derivate, deren hestellung und deren verwendung als inhibitoren des mikrosomalen triglycerid-transfer-proteins und/oder der apolipoprotein b (apo b) sekretion
GB9708805D0 (en) 1997-05-01 1997-06-25 Smithkline Beecham Plc Compounds
US5968950A (en) * 1997-06-23 1999-10-19 Pfizer Inc Apo B-secretion/MTP inhibitor hydrochloride salt
GB9810876D0 (en) 1998-05-20 1998-07-22 Smithkline Beecham Plc Compounds
CA2319495A1 (en) 1998-06-08 1999-12-16 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
WO2000021951A1 (en) 1998-10-08 2000-04-20 Smithkline Beecham Plc Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents)
GB9826412D0 (en) * 1998-12-03 1999-01-27 Glaxo Group Ltd Chemical compounds
WO2000038725A1 (en) * 1998-12-23 2000-07-06 G.D. Searle Llc Combinations for cardiovascular indications
HUP0201972A3 (en) * 1998-12-23 2005-06-28 G D Searle Llc Chicago Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
DE19929012A1 (de) * 1999-06-25 2000-12-28 Bayer Ag Kombination von MTP-Inhibitoren und stoffwechselbeeinflussenden Wirkstoffen und ihre Verwendung in Arzneimitteln
DE19929065A1 (de) * 1999-06-25 2000-12-28 Bayer Ag Kombination von MTP-Inhibitoren und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
DE19929031A1 (de) * 1999-06-25 2000-12-28 Bayer Ag Kombination von MTP-Inhibitoren und Lipidsenkern und ihre Verwendung in Arzneimitteln
WO2001005767A1 (en) * 1999-07-20 2001-01-25 Novartis Ag Organic compounds
CO5271688A1 (es) * 1999-11-10 2003-04-30 Pfizer Prod Inc Uso de inhibidor de secrecion de apoliproteinas b y/o de proteina de transferencia de trigliceridos microsmales
CA2324800A1 (en) * 1999-11-10 2001-05-10 Mary Anne Hickman Use of apo b secretion/mtp inhibitors
CA2324801A1 (en) * 1999-11-10 2001-05-10 Andrew Gordon Swick Use of apo b secretion/mtp inhibitors and anti-obesity agents
IL139450A0 (en) * 1999-11-10 2001-11-25 Pfizer Prod Inc Methods of administering apo b-secretion/mtp inhibitors
PT1259484E (pt) * 2000-01-18 2005-09-30 Novartis Ag Carboxamidas uteis como inibidores de proteina de transferencia de triglicerido microsomal e de secrecao de apolipoproteina b
CA2402431C (en) * 2000-03-14 2009-10-06 Actelion Pharmaceuticals Ltd 1,2,3,4-tetrahydroisoquinoline derivatives
AU2001262185A1 (en) * 2000-04-10 2001-10-23 Novartis Ag Substituted (hetero)aryl carboxamide derivatives as microsomal triglyceride transfer protein (mtp) and apolipoprotein b (apo b) secretion
GB0013346D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
GB0013383D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
AU2001277727A1 (en) * 2000-08-10 2002-02-25 Tanabe Seiyaku Co., Ltd. Benzoylaminoisoindoline compounds, processes for the preparation of the same andintermediates for the synthesis thereof
WO2002014277A1 (fr) * 2000-08-10 2002-02-21 Tanabe Seiyaku Co., Ltd. Composes de biphenylcarboxamidoisoindoline, procedes de preparation de ceux-ci et produits intermediaires destines a la synthese de ceux-ci
CZ2003593A3 (cs) * 2000-09-01 2003-05-14 Sankyo Company Limited Farmaceutický přípravek pro léčbu a prevenci xantomu a aterosklerózy
JO2654B1 (en) 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Multiple aryl caroxa amides are useful as lipid - lowering agents
CZ20031230A3 (cs) * 2000-10-05 2003-10-15 Fujisawa Pharmaceutial Co., Ltd Benzamidový derivát a farmaceutický prostředek
JO2409B1 (en) 2000-11-21 2007-06-17 شركة جانسين فارماسوتيكا ان. في Second-phenyl carboxy amides are useful as lipid-lowering agents
US20040157866A1 (en) * 2001-04-30 2004-08-12 Hisashi Takasugi Amide compounds
MXPA03011784A (es) 2001-06-22 2004-04-02 Pfizer Prod Inc Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros.
OA12626A (en) 2001-06-28 2006-06-13 Pfizer Prod Inc triamide-substituted indoles, benzofuranes and benzothiophenes as inhibitors of microsomal triglyceride transfer protein (MTP)and/or apolipoprotein B(APO B) secretion.
US20030144350A1 (en) * 2001-07-20 2003-07-31 Adipogenix, Inc. Fat accumulation-modulation compounds
WO2003013516A1 (en) * 2001-08-10 2003-02-20 Adipogenix, Inc. Fat accumulation-modulating compounds
US20050038035A1 (en) * 2001-11-28 2005-02-17 Hisashi Takasugi Heterocyclic amide compounds as apolipoprotein b inhibitors
KR100664822B1 (ko) * 2002-02-01 2007-01-04 화이자 프로덕츠 인코포레이티드 변형된 분무-건조 장치를 이용한 균질한 분무-건조된 고체비결정성 약물 분산액의 제조 방법
WO2003072532A1 (fr) 2002-02-28 2003-09-04 Japan Tobacco Inc. Compose d'esters et ses utilisation en medecine
US7241774B2 (en) * 2002-03-13 2007-07-10 University Of Tennessee Research Foundation Substituted tetrahydroisoquinoline compounds, methods of making, and their use
WO2004039795A2 (en) * 2002-10-29 2004-05-13 Fujisawa Pharmaceutical Co., Ltd. Amide compounds for the treatment of hyperlipidemia
BR0317323A (pt) * 2002-12-20 2005-11-16 Pfizer Prod Inc Inibidores de proteìna de transferência de triglicerìdeos microssomal
AU2003286347A1 (en) * 2002-12-20 2004-07-14 Pfizer Products Inc. Microsomal triglyceride transfer protein inhibitors
US7276536B2 (en) 2003-03-17 2007-10-02 Japan Tobacco Inc. Method for increasing the bioavailability of the active form of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino) phenyl] 2-methylpropanethioate
WO2005021486A1 (ja) 2003-08-29 2005-03-10 Japan Tobacco Inc. エステル誘導体及びその医薬用途
PL1751111T3 (pl) 2004-03-01 2015-06-30 Actelion Pharmaceuticals Ltd Podstawione pochodne 1,2,3,4-tetrahydroizochinoliny
NZ549721A (en) 2004-03-05 2010-08-27 Univ Pennsylvania Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
US20060030623A1 (en) * 2004-07-16 2006-02-09 Noboru Furukawa Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis
US8101774B2 (en) * 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof
WO2006046623A1 (ja) * 2004-10-25 2006-05-04 Japan Tobacco Inc. 溶解性及び安定性の改善された固形製剤及びその製造方法
EP1843819A2 (en) * 2004-11-15 2007-10-17 Obe Therapy Biotechnology S.A.S. Methods of reducing body fat
JP2006249022A (ja) 2005-03-11 2006-09-21 Sumitomo Chemical Co Ltd ４−（２−メチルフェニル）ベンゾトリフルオライドの製造方法
EP1877369B1 (en) 2005-04-19 2013-07-10 Surface Logix, Inc. Inhibitors of microsomal triglyceride transfer protein and apo-b secretion
JP2008542255A (ja) * 2005-05-27 2008-11-27 ファイザー・プロダクツ・インク 肥満症の治療または体重減量の維持のためのカンナビノイド−１受容体アンタゴニストおよびミクロソームトリグリセリド輸送タンパク質阻害物質の併用
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7919506B2 (en) 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
JP2009531314A (ja) * 2006-03-10 2009-09-03 ニューロジェン・コーポレーション ピペラジニルオキソアルキルテトラヒドロイソキノリン類および関連類似物
JP5198430B2 (ja) 2006-04-03 2013-05-15 サンタリス ファーマ アー／エス ａｎｔｉｍｉＲＮＡアンチセンスオリゴヌクレオチドを含む医薬組成物
MY162210A (en) * 2006-04-03 2017-05-31 Roche Innovation Ct Copenhagen As Pharmaceutical composition
CA2654183A1 (en) * 2006-06-02 2007-12-13 San Diego State University Research Foundation Compositions and methods for ameliorating hyperlipidemia
US20090042835A1 (en) * 2006-06-02 2009-02-12 Davis Roger A Compositions and methods for ameliorating hyperlipidemia
EP2076597A2 (en) * 2006-10-09 2009-07-08 Santaris Pharma A/S Rna antagonist compounds for the modulation of pcsk9
WO2008045564A2 (en) * 2006-10-12 2008-04-17 Epix Delaware, Inc. Carboxamide compounds and their use as antagonists of the chemokine ccr2 receptor
JO2653B1 (en) 2006-10-24 2012-06-17 شركة جانسين فارماسوتيكا ان. في Tetrahydroflavin 1-carboxylic acid substituted with pyridine or pyrazine inhibit MTB
KR101387459B1 (ko) * 2006-10-24 2014-05-14 얀센 파마슈티카 엔.브이. Ｍｔｐ를 저해하는 테트라하이드로-나프탈렌-1-카복실산 유도체
CN101663262B (zh) 2006-12-01 2014-03-26 百时美施贵宝公司 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
WO2008075949A1 (en) * 2006-12-20 2008-06-26 Friesland Brands B.V. Modulation of human microsomal triglyceride transfer protein (mtp or mttp) gene expression by food-grade/ingested dietary microorganisms
EP2120927A1 (en) * 2006-12-21 2009-11-25 Aegerion Pharmaceuticals, Inc. Methods for treating obesity with a combination comprising a mtp inhibitor and a cholesterol absorption inhibitor
WO2008113832A2 (en) * 2007-03-22 2008-09-25 Santaris Pharma A/S SHORT RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF TARGET mRNA
JP2010521193A (ja) * 2007-03-22 2010-06-24 サンタリス ファーマ アー／エス Ａｐｏ−ｂ１００発現の阻害のためのｒｎａアンタゴニスト化合物
EP2162451A4 (en) * 2007-06-25 2012-04-18 Neurogen Corp PIPERAZINYL-OXOALKYL-TETRAHYDRO-BETA-CARBOLINE AND RELATED ANALOGUE
AU2008292091A1 (en) * 2007-08-30 2009-03-05 Santaris Pharma A/S RNA antagonist compounds for the modulation of FABP4/aP2
ES2463665T3 (es) 2007-10-04 2014-05-28 Stella Aps Tratamiento de combinación para el tratamiento de infección por virus de la hepatitis C
DK2225261T3 (en) 2007-12-03 2016-06-06 Obe Therapy Biotechnology Borpeptidinhibitorer of enteropeptidase and their uses in the treatment of obesity, obesity and / or disorders associated with abnormal lipid metabolism
CN101925383A (zh) 2007-12-11 2010-12-22 赛特帕斯凡德株式会社 甲酰胺化合物及其作为趋化因子受体激动剂的应用
US20090197947A1 (en) * 2008-02-01 2009-08-06 The Research Foundation Of State University Of New York Medicaments and methods for lowering plasma lipid levels and screening drugs
AU2009221064B2 (en) * 2008-03-07 2014-12-11 Roche Innovation Center Copenhagen A/S Pharmaceutical compositions for treatment of microRNA related diseases
EP2315832B1 (en) 2008-08-01 2015-04-08 Roche Innovation Center Copenhagen A/S Micro-rna mediated modulation of colony stimulating factors
ES2599979T3 (es) * 2009-04-24 2017-02-06 Roche Innovation Center Copenhagen A/S Composiciones farmacéuticas para el tratamiento de pacientes de VHC que no responden al interferón
WO2011009697A1 (en) 2009-07-21 2011-01-27 Santaris Pharma A/S Antisense oligomers targeting pcsk9
KR101695582B1 (ko) 2013-04-17 2017-01-13 화이자 인코포레이티드 심혈관 질환을 치료하기 위한 n-피페리딘-3-일벤즈아미드 유도체
RS59986B1 (sr) 2013-06-27 2020-03-31 Roche Innovation Ct Copenhagen As Antisens oligomeri i konjugati koji ciljno deluju na pcsk9
WO2015065595A1 (en) 2013-10-30 2015-05-07 Trustees Of Dartmouth College Method for selectively inhibiting acat1 in the treatment of obesity, metabolic syndrome, and atherosclerosis
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
CA2965336A1 (en) * 2014-10-22 2016-04-28 The Board Of Regents Of The University Of Texas System Small-molecule inhibitors targeting discoidin domain receptor 1 and uses thereof
JOP20210193A1 (ar) 2019-01-18 2023-01-30 Astrazeneca Ab مثبطات pcsk9 وطرق استخدامها
CN113292493A (zh) * 2021-06-23 2021-08-24 上海立科化学科技有限公司 5,7-二氯-1,2,3,4-四氢异喹啉的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022900A (en) * 1970-09-09 1977-05-10 Marion Laboratories, Inc. Compositions containing 1,2,3,4-tetrahydroisoquinolines used as hypotensive agents
US5595872A (en) * 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
US5739135A (en) * 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
WO1996040640A1 (en) * 1995-06-07 1996-12-19 Pfizer Inc. BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION

Also Published As

Publication number Publication date
US6121283A (en) 2000-09-19
AR010309A1 (es) 2000-06-07
IL129744A0 (en) 2000-02-29
TR199901180T2 (xx) 1999-08-23
TW502023B (en) 2002-09-11
BG108830A (bg) 2005-10-31
WO1998023593A1 (en) 1998-06-04
ID18995A (id) 1998-05-28
SK65499A3 (en) 2001-05-10
OA11050A (en) 2002-03-07
PA8441601A1 (es) 2000-05-24
CN1380289A (zh) 2002-11-20
AP9701145A0 (en) 1998-01-31
AU716151B2 (en) 2000-02-17
BG103434A (en) 2000-07-31
AU4634797A (en) 1998-06-22
UY24789A1 (es) 2000-09-29
HRP970642A2 (en) 1998-10-31
NO992525L (no) 1999-05-26
PE17199A1 (es) 1999-02-19
GT199700122A (es) 1999-05-19
DZ2358A1 (fr) 2002-12-28
JP3270764B2 (ja) 2002-04-02
CZ292160B6 (cs) 2003-08-13
EA001539B1 (ru) 2001-04-23
NO312760B1 (no) 2002-07-01
BR9714364A (pt) 2000-03-21
CA2272719C (en) 2002-10-01
CA2272719A1 (en) 1998-06-04
TNSN97193A1 (fr) 2005-03-15
EA199900416A1 (ru) 1999-12-29
HN1997000144A (es) 1997-12-16
JP2000505810A (ja) 2000-05-16
NO992525D0 (no) 1999-05-26
CN1238764A (zh) 1999-12-15
NZ335162A (en) 2000-01-28
MA26451A1 (fr) 2004-12-20
AP804A (en) 2000-01-28
ZA9710641B (en) 1999-05-26
IS5040A (is) 1999-04-30
EP0944602A1 (en) 1999-09-29
KR100334567B1 (ko) 2002-05-03
KR20000057269A (ko) 2000-09-15

Similar Documents

Publication Publication Date Title
YU23499A (sh) Inhibitorski amidi apo-b-sekrecije/mtp-a
EP1090908A3 (en) Cyclobutane derivatives as inhibitors of protein farnesyltransferase
IL111455A0 (en) Substituted heterocyclic carboxamide esters, theirpreparation and their use as pharmaceuticals
PT882707E (pt) Novos compostos trciclicos e composicoes medicamentosas contendo os mesmos
PT84975A (en) Trans-6-]2-(3-or 4-carboxamido-substituted pyrrol-1-yl) alkyl)-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
MX9702175A (es) Combinacion de un inhibidor de absorcion de colesterol y un inhibidor de sintesis de colesterol.
CA2356158A1 (en) Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
NZ235323A (en) Amide derivatives and pharmaceutical compositions thereof
WO1998040375A3 (en) COMBINATION OF ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS
YU9802A (sh) Inhibitori ćelijske adhezije
IL111454A0 (en) Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
AU4876096A (en) Process for the distillation of alcohols
DE69704057D1 (de) Terphenylverbindungen und sie enthaltende arzneimittel
MXPA01006469A (es) Combinaciones de inhibidores de proteina de transferencia de ester colesterilico y derivados de acido fibrico para indicaciones cardiovasculares.
HU9603451D0 (en) Lactam inhibitors of cholesterol esterase
BR9809143A (pt) Processo para sintetizar composto
CO4650034A1 (es) Amidas inhibidoras de la secrecion de apo b/mtp
ECSP972325A (es) Amidas inhibidoras de la secrecion de apo b/mtp
DE69405760D1 (de) 4-aza-pregnan-5-alpha-reductase isozym 1 inhibitoren